按相关排序
全部格式
全部页数
时间不限
只看优质
只看可投资
展开
排序：
相关 最多阅读 最新上传
格式：
全部 doc pdf ppt xls txt 豆单
页数：
全部 1-8页 9-100页 100页以上
时间：
全部 2024年 2023年 2022年及以前
8
CCO_Clin_Phase III J-ALEX Alectinib vs Crizotinib in ALK Inhibitor-Na.ppt
CCOIndependent Conference Coverage*of 2016ASCO Annual Meeting, June 2016PhaseIII J-ALEX: Alectinib v
立即下载
25
alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (alk ) non-small-cell lung cancer cns efficacy results from the.pdf
Alectinibversus crizotinib treatment-naveanaplastic lymphoma kinase-positive (ALK+) non-small-cell l
立即下载
11
The-Lancet_2017_Alectinib-versus-crizotinib-in-patients-with-ALK-positive-non-small-cell-lung-cancer-J-ALEX-an-open-label-randomised-phase-3-trial.pdf
The-Lancet_2017_Alectinib-versus-crizotinib-in-patients-with-ALK-positive-non-small-cell-lung-cancer-J-ALEX-an-open-label-randomised-phase-3-trialThe-Lancet_2017_Alectinib-versus-crizotinib-in-patients-with-ALK-positive-non-small-cell-lung-cancer-J-ALEX-an-open-label-randomised-phase-3-trialThe-Lancet_2017_Alectinib-versus-crizotinib-in-patients-with-ALK-positive-non-small-cell-lung-cancer-J-ALEX-an-open-label-randomised-phase-3-trial
立即下载
24
Alectinib.pdf
本文收录的Alectinib推荐剂量为每天2次，每次300mg；用于治疗非小细胞肺癌（NSCLC）；是一种间变性淋巴瘤激酶（ALK）抑制剂；包含了销量，化合物，晶型，及其适应症专利等信息；还收录了1条原研路线，2条创新型化学合成路线；在 X 射线荧光光谱分析 仪中显示，Alectinib 与 ALK 的 ATP 结合位点相结合（IC50 = 1.9 nM）；在大 鼠（F% = 88.6%）和猴（F% =50.4%）体内的生物利用度较高；在大鼠中，母体和胎儿的NOAEL值均为3 mg/kg/天；在兔中，母体和胎儿的NOAEL值均为9 mg/kg/天；分别是人体暴露量的0.9和0.4倍。
立即下载
20
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer a single-group, multicentre, phase 2 trial.pdf
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer a single-group, multicentre, phase 2 trial
立即下载
14
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.pdf
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer
立即下载
9
patient-reported outcomes from the randomized phase iii alex study of alectinib versus crizotinib in patients with alk-positive non-small-cell lung.pdf
patient-reported outcomes from the randomized phase iii alex study of alectinib versus crizotinib in patients with alk-positive non-small-cell lung
立即下载
6
pooled overall survival and safety data from the pivotal phase ii studies (np28673 and np28761) of alectinib in alk-positive non-small-cell lung ca.pdf
pooled overall survival and safety data from the pivotal phase ii studies (np28673 and np28761) of alectinib in alk-positive non-small-cell lung ca
立即下载
5
final progression-free survival results from the j-alex study of alectinib versus crizotinib in alk-positive non-small-cell lung cancer.[2020][lung.pdf
final progression-free survival results from the j-alex study of alectinib versus crizotinib in alk-positive non-small-cell lung cancer.[2020][lung
立即下载

向豆丁求助：有没有Alectinib?

95%的用户最终下载了:
如要投诉违规内容，请联系我们按需举报；如要提出意见建议，请到社区论坛发帖反馈。